Sebastian Liehr is currently an Associate Director for Global Portfolio Planning at Santen, where he is currently responsible for Portfolio management and strategic planning of the global retina portfolio. He previously worked on the US commercialization strategy for Opsiria, Santen’s Ph3 asset for posterior uveitis as well as other products in various stages of development. Prior to his role at Santen, Sebastian worked at BD Biosciences and at BASF Venture capital in market research and analysis. His career started as a medicinal chemist working on Hepatitis C drugs and antibiotics at Genelabs Technologies. Sebastian holds an undergraduate degree in Chemistry from the Technical University Berlin, Germany, a PhD in organic chemistry from University of Delaware and a MBA from Santa Clara University. He also completed postdoctoral training in biochemistry at the University of Pennsylvania.